Estrogen patches with ARPIs confirmed comparable PSA responses and security in comparison with LHRHa plus ARPIs in metastatic prostate most cancers, per STAMPEDE trial findings.
Sufferers with metastatic prostate most cancers confirmed comparable prostate-specific antigen (PSA) responded when handled with transdermal estradiol (tE2) patches and androgen receptor pathway inhibitors (ARPIs), comparable to Zytiga (abiraterone), Xtandi (enzalutamide) or Erleada (apalutamide), in comparison with therapy with luteinizing hormone releasing hormone analogues (LHRHa) and ARPI, analysis has proven.
These findings, offered on the 2025 ASCO Genitourinary Cancers Symposium, help using tE2 patches for androgen deprivation remedy (ADT) in prostate most cancers administration, researchers posit, noting that tE2 patches present sufferers with EFT selections about anticipated toxicity profiles and mode of administration.
“Estrogen is, after all, the oldest anti-cancer drug, relationship again to the Forties and the rationale that we’re been evaluating transdermal estrogen is that by switching from oral to patches, you abrogate the cardiovascular thromboembolic issues that you simply see with oral therapies, and you may nonetheless, in the event you use two to a few patches, suppress testosterone all the way down to castrate ranges,” mentioned presenting creator Nicholas David James, of The Institute of Most cancers Analysis and The Royal Marsden Hospital NHS Basis Belief in London, throughout a fast oral summary presentation of the information on the symposium.
Glossary:
Prostate-specific antigen: a protein related to the presence of prostate most cancers within the physique.
Transdermal estradiol patches: an estrogen patch.
Androgen receptor pathway inhibitors: therapies that block the consequences of male hormones, referred to as androgens, to cease the expansion and unfold of tumor cells.
Luteinizing hormone releasing hormone analogues: substance that forestall the making of intercourse hormones.
Androgen deprivation remedy: therapy to scale back the extent of andorgens within the physique.
Gynecomastia: enlargement of male breast tissue.
Pruritis: itching.
Within the multi-arm, multi-stage part 2 platform STAMPEDE trial, 79 sufferers with histologically confirmed M1 prostate most cancers between October 2020 and March 2023 obtained both LHRHa+ARPI (41 sufferers) or tE2+ARPI (38 sufferers). Baseline traits have been comparable, with median ages of 69 within the LHRA+ARPI arm and 69 within the tE2+ARPI arm, and PSA at baseline of 47 and 39, respectively.
Within the LHRHa+ARPI arm, 25 of 41 sufferers, or 61%, achieved a PSA of 0.2 ng/ml or much less, and this was achieved by 23 of 38, of 61%, of sufferers within the tE2+ARPI arm.
Within the LHRHa and tE2 arms, PSA90 charges have been 93% versus 95% and PSA50 charges have been 100% and 100%. Moreover, 31 of 34, or 91%, of sufferers handled with tE2 had testosterone of 1.7nj/ml or much less at 12 weeks.
“It is efficient as measured right here, it is protected. There have been no security indicators for the interplay. We predict it is an alternate remedy selection for males beginning ADT,” James mentioned.
Amongst sufferers within the LHRHa and tE2 arms, charges of scorching flashes of any grade have been skilled by 54% and 18% of sufferers, gynecomastia of any grade was skilled by 10% and 45%, hypertension of any grade was skilled by 20% and 5%, and pruritis of any grade was skilled by 5% and 21%.
Within the research, contributors have been randomly allotted to tE2 patches releasing 100mcg/24hrs, three patches modified twice-weekly as soon as testosterone 1.7ng/ml or much less, or normal doses of LHRHa and scheduled to obtain ARPIs.
The first consequence of the research was the proportion of sufferers who reached a PSA nadir of 0.2ng/ml or much less throughout the first six months, with researchers noting that different PSA parameters, testosterone 1.7ng/ml or much less at 12 weeks with tE2, and uncomfortable side effects throughout the first 12 months (together with hypertension, scorching flashes and gynecomastia) have been assessed.
“The takeaway conclusions are that [tE2] is efficient on the measure we have chosen, which is PSA lower than 0.2 at 24 weeks,” James mentioned. “It is protected, there have been no sudden hostile occasions noticed, and we predict it is a viable different selection, notably for instance, in the event you’re self-paying in your remedy, but additionally for different causes as properly, it is very low-cost.”
Reference:
“Transdermal oestradiol (tE2) patches as androgen deprivation remedy (ADT): Efficacy and security of mixing with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate most cancers—Randomised comparability from the STAMPEDE trial platform.” offered by Nicholas David James on the 2025 ASCO Genitourinary Cancers Symposium, Feb. 13-15, San Francisco, California, summary 21.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
